Oral small molecule (RBP4 antagonist)Belite Bio

Tinlarebant

Tinlarebant is an oral, once-daily RBP4 antagonist designed to reduce the retinal accumulation of toxic vitamin-A byproducts. It is Belite Bio's lead candidate for Stargardt disease and geographic atrophy.

Also known as: LBS-008

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Indications

Targets

Tinlarebant forecasting benchmarks

1 benchmark

ResolvedPhase 3

DRAGON Phase 3: tinlarebant (5 mg daily) in adolescent Stargardt disease type 1 (STGD1)

Tinlarebant · Stargardt disease

Dec 1, 2025Clinical Trials

Mechanism & molecular targets

RBP4· gene

Indications studied

Stargardt disease· STGD1

Developed by

Belite Bio· BLTE

About Tinlarebant

What is Tinlarebant?

What does Tinlarebant target?

Tinlarebant acts on Retinol-binding protein 4 (RBP4).

How well do AI models predict Tinlarebant trial outcomes?

Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.